Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19294461 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AACLY | |
| SCHEMBL16491137 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AACLY | |
| SCHEMBL1781960 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AACLY | |
| SCHEMBL1824574 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AACLY | |
| SCHEMBL12189609 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AACLY | |
| SCHEMBL1783238 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AACLY | |
| SCHEMBL1784550 | 0.97 | TSHR (0.48) | TSHRFAAHTRPV1HIF1AACLY | |
| Ammonia Solution, Strong SCHEMBL29011533 | 0.95 | TSHR (0.46) | TSHRFAAHTRPV1HIF1AACLY | |
| Iodide SCHEMBL28870826 | 0.92 | TSHR (0.44) | TSHRFAAHTRPV1HIF1AACLY | |
| SCHEMBL1784079 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3109254-B1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | UNIV OSAKA (JP) | 2018-04-11 | — | — | EP | claimed |
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024101446-A1 | MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME | ルクサナバイオテク株式会社 | 2024-05-16 | — | — | WO | disclosed |
| CN-112513062-B | Oligonucleotide-containing small cell lung cancer therapeutic agent | 国立大学法人大阪大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20240148775-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | OSAKA UNIVERSITY (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-117964673-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964674-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-11939421-B2 | Or relating to curing agents | HEXCEL COMPOSITES LIMITED (GB) | 2024-03-26 | — | — | US | disclosed |
| US-11879052-B2 | Curatives | HEXCEL COMPOSITES LIMITED (GB) | 2024-01-23 | — | — | US | disclosed |
| US-11866705-B2 | Small cell lung cancer therapeutic agent containing oligonucleotide | Osaka Univerity (JP) | 2024-01-09 | — | — | US | disclosed |
| EP-0795326-A1 | OCULAR TENSION DEPRESSANT | SANKYO COMPANY LIMITED (JP) | 1997-09-17 | — | — | EP | disclosed |
| CN-1157286-A | N,N-dimethyl-1-t-butoxycarbonyl-4-phenylpiperidine-4-carboxamide | SANKYO CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
| CN-1148809-A | intraocular pressure lowering agent | SANKYO CO (JP) | 1997-04-30 | — | — | CN | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| CN-1102640-A | Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory and psychiatric disorders | SANKYO CO (JP) | 1995-05-17 | — | — | CN | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0156100-B1 | 3-SUBSTITUTED HYDROXYPENTANEDIOIC ACIDS, -HEMIESTERS OR -ANHYDRIDES | G.D. Searle & Co. (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4554359-A | 3-Substituted pentanedioic acids and derivatives thereof | G. D. SEARLE & CO. (US) | 1985-11-19 | — | — | US | disclosed |
| EP-0156100-A2 | 3-Substituted hydroxypentanedioic acids, -hemiesters or -anhydrides | G.D. Searle & Co. (US) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148775-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | UPF1, RBM17, NSUN2 | TSHR 3099/4885FAAH 4761/4885TRPV1 3587/4885 |
| US-11939421-B2 | Or relating to curing agents | FABP4, RARA, ADIPOR1 | TSHR 4021/4885FAAH 263/4885TRPV1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.